First patient treated in the study of Amphinex in patients with bile duct cancer (Cholangiocarcinoma)

Oslo, 4 February 2014 - PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been treated in the phase I/II study of Amphinex in combination with the cytotoxic agent gemcitabine in patients with bile duct cancer (cholangiocarcinoma). The first patient was treated at the University Hospital Aintree, Liverpool, UK.

Coordinating Investigator, Dr. Richard Sturgess at Aintree, said: "Bile duct cancer is a devastating disease with a very clear need of better treatment methods. Bile duct cancer has a remarkable resistance to chemotherapy and these patients are lacking good alternative treatment options. PCI of gemcitabine with Amphinex represents a new and innovative treatment concept that could potentially produce significant local tumour response in these patients. The study is well designed to demonstrate the potential clinical benefit of Amphinex induced PCI of gemcitabine in bile duct cancer patients and I look forward to working with my fellow investigators on this study."

Per Walday, CEO of PCI Biotech, said: "This is a very important milestone for PCI Biotech. We are confident that PCI treatment has the potential to provide clinical benefit in several different indications. Bile duct cancer has been chosen due to the high need of new local treatment options for this disease combined with a very good fit with the PCI technology."